PTSD Clinical Trial - MDMA-assisted Brief Cognitive Behavioral Conjoint

Status Recruiting

Clinical Trial Summary

The goal of this pilot trial is to examine the preliminary effectiveness of MDMA-facilitated bCBCT for improving chronic PTSD and relationship functioning in a sample of veterans and their intimate partners seeking care within the VA San Diego Healthcare System.

Clinical Trial Description

The pilot study is a single site, open-label study assessing the preliminary effectiveness, safety, and acceptability of MDMA-assisted therapy in combination with brief Cognitive Behavioral Conjoint Therapy in a sample of 8 veterans diagnosed with PTSD and their intimate partners (N = 16) within the Veterans Affairs San Diego Healthcare System (VASDHS). Therapy teams will deliver the 8 session bCBCT intervention combined with two full-day MDMA sessions for the Veteran diagnosed with PTSD. The veteran with PTSD will be given 80 mg of MDMA HCl with a 40 mg MDMA HCl supplemental dose in the first session and 100 mg of MDMA HCl with a supplemental dose of 40 mg MDMA HCl in the second. The intimate partner will be present for the MDMA sessions (unless they decline or it is clinically contraindicated) but will not receive MDMA. The couples will complete one preparatory session and at least two Emotion Focused Integrative sessions (five max). The PTSD+ veteran will receive telephone check-in calls every other business day for one week following each MDMA session. The first MDMA session occurs in the morning the business day after the preparatory session and the second MDMA session occurs in the morning within 5 business days after bCBCT Session 7. The Emotion-Focused Integrative Sessions take place the morning after each MDMA session. Outcomes examining PTSD symptom severity and relationship functioning will be evaluated for preliminary effectiveness. The study's screening, enrollment, and baseline phase lasts from pre-screen to baseline (approximately 12 weeks, +/- 2 weeks). The treatment period lasts from bCBCT Session 1 to bCBCT Session 8 (7 weeks + 6 weeks). The follow-up period lasts from the post-treatment assessment to study termination (24 weeks +/- 30 days). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05979844
Study type	Interventional
Source	San Diego Veterans Healthcare System
Contact	Leslie Morland
Phone	858-226-5765
Email	Leslie.Morland@va.gov
Status	Recruiting
Phase	Phase 3
Start date	October 6, 2023
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03962504` - Written Exposure Therapy Versus Prolonged Exposure: a Non-inferiority Trial	N/A
Completed	`NCT01995123` - Behavioral Activation for Smoking Cessation in PTSD	N/A
Not yet recruiting	`NCT06278922` - Evaluating Signs of Safety: A Deaf-Accessible Therapy Toolkit for AUD and Trauma	N/A
Completed	`NCT04597450` - Lu AG06466 in Participants With Post Traumatic Stress Disorder (PTSD)	Phase 1
Completed	`NCT03593772` - Mission Reconnect- Delivering a Mobile and Web Based Self Directed Complementary And Integrative Health Program to Veterans and Their Partners to Manage Pain and PTSD	N/A
Completed	`NCT03429166` - Connecting Women to Care: Home-based Psychotherapy for Women With MST Living in Rural Areas	N/A
Recruiting	`NCT04317820` - Deep Brain Reorienting in Post-traumatic Stress Disorder	N/A
Active, not recruiting	`NCT04588883` - Strengthening Families Living With HIV in Kenya	N/A
Completed	`NCT03504722` - Evaluating the Feasibility of RESCUE: An Adjunctive HAI-Based Intervention for Veterans With PTSD	N/A
Completed	`NCT04305353` - Intensive Care Unit (ICU) Diary Project	N/A
Completed	`NCT03113890` - McLean and Genomind Prospective Study	N/A
Withdrawn	`NCT05173831` - Study of Feasibility and Safety of MDMA-Assisted Group Therapy for the Treatment of PTSD in Veterans	Phase 2
Not yet recruiting	`NCT04056767` - Changes in Digital Phenotype During PE Therapy
Withdrawn	`NCT03924297` - Chilipad for Sleep and Symptoms of PTSD	N/A
Withdrawn	`NCT03216356` - Effect of D-cycloserine on a Short Imagery Rescripting Intervention for Subclinical PTSD	Phase 2/Phase 3
Completed	`NCT03158558` - Intensive Weekend Retreat Multi-Couple Group Therapy for PTSD	N/A
Completed	`NCT03343028` - Biomarker Establishment for Superior Treatment of PTSD
Completed	`NCT02370173` - A Non-Pharmacological Method for Enhancing Sleep in PTSD	N/A
Withdrawn	`NCT01957371` - Mindful Yoga Therapy for Veterans With PTSD and Pain	N/A
Completed	`NCT01911585` - Efficacy of 60-minute Versus 90-minute Sessions in Treating PTSD Using Prolonged Exposure	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

MDMA-assisted Brief Cognitive Behavioral Conjoint Therapy for PTSD — MDMA-bCBCT

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms